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Abstract. Background: Telomerase reverse transcriptase
(TERT) has a well-known role in carcinogenesis due to its
functions in inducing cell immortality and preventing
senescence. In this study, the relationships between TERT
and a panel of known stem cell markers was examined in
order to direct future enquiries into the role of ‘stem-ness’
in human breast cancer. Materials and Methods: Breast
cancer tissues (n=124) and adjacent normal tissues (n=30)
underwent reverse transcription and quantitative
polymerase chain reaction. Transcript levels were analyzed
for the correlation with that of TERT. Results: A significant
direct correlation was found in cancerous tissue between
TERT and BMI1 proto-oncogene polycomb ring finger 4
(BMI1; n=88, p<0.001), nestin (NES; n=88, p<0.001),
POU domain, class 5, transcription factor 1 (POU5F1;
n=88, p<0.001), aldehyde dehydrogenase 1 family member
A2 (ALDH1A2; n=87, p=0.0298), cyclin-dependent kinase
inhibitor 1A (CDKN1A; n=88, p<0.001), integrin subunit
beta 1 (ITGNB1; n=88, p<0.001), integrin subunit alpha 6
(ITGA6; n=88, p<0.001), cluster of differentiation antigen
24 (CD24; n=88, p=0.0114), MET proto-oncogene (MET;
n=78, p<0.001) and noggin (NOG; n=88, p<0.001).
Conclusion: The evidence presented in this article of
possible interactions between TERT and a discrete subset of
known stem cell markers would significantly contribute to
further enquiries regarding clonal dynamics in the context
of human breast cancer.
Breast cancer continues to be a major cause of pathology in
women. It is the most common cause of invasive cancer in
females, with two million newly-diagnosed cases worldwide
in 2018 (1). It is the second most common cause of cancer-
related mortality for females in the UK, accounting for 15%
of all cancer-related deaths in women in 2016 (2). However,
it has to be acknowledged that survival has improved over
the past several decades due to advances in treatment (3).
A greater understanding of the molecular pathways
underlying breast cancer has been fundamental to many of
these advances. The recognition of breast cancer as a diverse
collection of diseases characterised by distinct molecular
signatures has been an important recent development. This
finding was the basis for the recent development of genomic
assays for breast cancer, which have greatly improved
prognostication and decision-making with regards to
adjuvant chemotherapy (4). In addition, this highlights the
potential role for tailored treatment of breast cancer on the
basis of specific pathways which may be involved (5). 
Human telomerase reverse transcriptase (TERT) is a
molecule with a role in cell aging and immortality. By virtue
of its function, it is expected to have a role in oncogenesis.
This was borne out by the results of our previous study, in
which we found the mRNA expression of TERT in breast
cancer samples to be associated with poor prognosis (6).
Neoplastic lesions, by virtue of their high cellular
turnover, have cells which acquire a degree of pluripotency
reminiscent of stem cells (‘stem-ness’). According to the
stem cell theory regarding oncogenesis, such cells may have
role in maintaining cellular turnover, and may have a
profound implication in the development of tailored and
targeted treatments for breast cancer (7). 
In this study, we aimed to examine the role of TERT in the
context of cancer-related cellular pluripotency by studying the
relations of TERT mRNA expression levels in breast cancer
samples with a panel of 30 known stem cell marker molecules
previously studied in the context of breast cancer (7-9).
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Materials and Methods
Samples. Tissue samples were collected after informed consent
with ethical approval as per contemporaneous institutional
guidelines (Bro Taf Health Authority ethics approval numbers
01/4303 and 01/4046). Immediately after surgical excision, a
tumour sample was taken from the tumour area. Another was taken
from the background non-cancerous tissue within 2 cm of the
tumour, without affecting the assessment of tumour margins in
order to serve as controls for comparison with the cancerous tissue.
Breast cancer tissues (n=124) and normal background tissues
(n=33) were collected and stored at −80˚C in liquid nitrogen until
analysis. This cohort has been the subject of a number of
completed and on-going studies (6, 10, 11). 
All the patients were treated according to local guidelines,
following discussions in multidisciplinary meetings (12). Patients
undergoing breast-conserving surgery also underwent radiotherapy.
Patients with hormone-sensitive disease were given tamoxifen.
Hormone-insensitive cases, high-grade cancer, and node-positive
cases were treated with adjuvant therapy. Clinicopathological data
(Table I) were collected from the patient charts and collated in an
encrypted database (7, 13).
Tissue processing, RNA extraction and cDNA synthesis. RNA
extraction kits and reverse transcription kits were obtained from
AbGene Ltd. (Epsom Surrey, UK). Custom made hot-start Master
Mix for quantitative polymerase chain reaction (qPCR) was from
AbGene Ltd (Epsom, Surrey, UK).
The literature was reviewed to identify known stem cell markers
which were included in the panel of molecules studied for
correlations with TERT: 30 were selected in all. They are
enumerated in Table II (14-40).
Approximately 10 mg of cancerous tissue was homogenised. A
larger amount of matched normal tissue (20-50 mg) was used as its
high fat content made it difficult to obtain sufficient RNA for
analysis. The concentration of RNA was determined using a UV
spectrophotometer (Wolf Laboratories, York, UK) to ensure
adequate amounts of RNA for analysis. Reverse transcription was
carried out using a reverse transcription kit (AbGene) with an
anchored olig (dT) primer using 1 mg of total RNA in a 96-well
plate to produce cDNA. The quality of cDNA was verified using β-
actin primers (primers 5’-ATGATATCGCCGCGCTCGTC-3’ and 5’-
CGCTCGGTGAGGATCTTCA-3’) (7, 13).
Quantitative analysis. Transcripts of cDNA library were determined
using real-time qPCR based on Amplifluor technology. The PCR
primers were designed using Beacon Designer software (Premier
Biosoft International Ltd., Palo Alto, CA, USA), but an additional
sequence, known as the Z sequence (5’-ACTGAACCTGA
CCGTACA-3’), which is complementary to the universal Z probe
(Intergen Inc., Oxford, UK) was added to the primer. The primers were
synthesized by Invitrogen Ltd. (Paisley, UK). 
The reaction was carried out under the following conditions:
94˚C for 12 min and 50 cycles of 94˚C for 15 s, 55˚C for 40 s, and
72˚C for 20 s. The levels of each transcript were generated from a
standard that was simultaneously amplified within the samples.
Levels of expressions of the molecules being studied were
normalised against cytokeratin 19 (CK19).
With every PCR run, a negative and positive control was
employed, using a known cDNA sequence (podoplanin) (7, 13).
The samples were selected out of a cohort of 124 samples.
However, some samples had to be excluded due to spurious results
caused by depletion of the sample or issues with pipetting or the
apparatus.
Statistical analysis. Correlations between TERT and molecules on the
stem cell panel was performed using the SigmaPlot 11 statistical
software package (Systat Software Inc., Hounslow, UK). Correlations
were studied using the Spearman rank correlation test. The transcript
levels of stem-cell related molecules within the breast cancer
specimens were compared to the mRNA expression of TERT. All
samples in the cohort were included. However, some specimens had
to be excluded due to spurious results caused by depletion of the
sample or due to errors in the PCR readings due to pipetting errors.
Correlations with p-Values less than 0.05 were considered significant. 
Results 
Spearman rank correlation test showed that TERT had significant
direct correlations with the expressions of BMI1 proto-oncogene
polycomb ring finger 4 (BMI1; r=0.581, n=88, p<0.001), nestin
(NES; r=0.581, n=88, p<0.001), POU domain, class 5,
transcription factor 1 (POU5F1; r=651, n=88, p<0.001),
aldehyde dehydrogenase 1 family member A2 (ALDH1A2;
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Table I. Description of clinical cohort.
Parameter                                                                   Number of samples
Tissue type
  Background, normal                                                              30
  Tumour                                                                                124
Tumour grade
  1                                                                                             24
  2                                                                                             42
  3                                                                                             58
Nottingham prognostic index
  Grade 1                                                                                  68
  Grade 2                                                                                  38
  Grade 3                                                                                  16
  Unknown                                                                                 2
TNM Stage
  1                                                                                             70
  2                                                                                             40
  3                                                                                               7
  4                                                                                               4
  Unknown                                                                                 3
Histology
  Ductal                                                                                    94
  Lobular                                                                                  14
  Other                                                                                      16
Patient outcome
  Alive and well                                                                       85
  Metastatic disease                                                                   7
  Death from breast cancer                                                      15
  All poor outcomes (Metastatic disease                               27
  and disease-related mortality)
TNM: Tumour, node and metastases staging (12).
r=0.233, n=87, p=0.0298), Cyclin dependent kinase inhibitor 1A
(CDKN1A; r=0.611, n=88, p<0.001), integrin subunit beta 1
(ITGNB1; r=0.476, n=88, p<0.001), Integrin subunit alpha 6
(ITGNA6; r=0.663, n=88, p<0.001), cluster of differentiation
antigen 24 (CD24; r=0.269, n=88, p=0.0114), MET proto-
oncogene (MET; r=0.591, n=78, p<0.001) and NOGGIN (NOG;
r=0.421, n=88, p<0.001) (Table II).
Discussion
Telomeres are the straight portions at the end of a
chromosome and are composed of repeating segments of
nucleotides. During mitosis, DNA polymerase is unable to
replicate this portion of the genome, which leads to genomic
instability and senescence. The telomeres are repaired by a
specialised enzyme referred to as TERT, which is a
multimeric molecule resident in the nucleus (41). TERT
enables the cell to continue to proliferate without undergoing
senescence, thereby achieving cell immortality (42). 
Cell immortality represents an important gain of function
for neoplastic cells. Indeed 70-90% of neoplastic lesions and
cancer cell lines surveyed in one study were found to have
increased activity of TERT (43). In another study, Elkak et
al. found high mRNA expression of TERT to be associated
with poorer outcomes in human breast cancer (6). Telomere-
lengthening, with consequent replicative immortality has
been characterised as a prerequisite for oncogenesis, with
TERT-mediated telomere lengthening being identified as a
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Table II. Correlations of mRNA expression (normalised to that cytokeratin 19) of stem cell markers with that of telomerase reverse transcriptase
(TERT) by the Spearman rank correlation test.
Gene symbol                                           Molecule encoded                                          Correlation                 p-Value                   No. of           Citation
                                                                                                                                     coefficient (R)                                             samples
CD24                                               Cluster of differentiation 24                                      0.269                     0.0114                          88                  (16)
ITGB1                                                  Integrin subunit beta 1                                           0.476                     0.0000034                    88                  (16)
CD44                                               Cluster of differentiation 44                                   −0.0185                   0.861                            91                  (17)
ITGA6                                                 Integrin subunit alpha 6                                          0.663                     0.0000002                    88                  (16)
BMI1                                 BMI1 proto-oncogene polycomb ring finger 4                        0.581                     0.0000000014             88                  (18)
NES                                                                   Nestin                                                        0.581                     0.0000000013             88                  (19)
POU5F1                            POU domain, class 5, transcription factor 1.                         0.651                     0.0000002                    88                  (20)
ALDH1A2                        Aldehyde dehydrogenase 1 family member A2                       0.233                     0.0298                          87                  (21)
MET                                                      MET proto-oncogene                                            0.591                     0.000000016                76                  (23)
CDKN1A                                Cyclin-dependent kinase inhibitor 1A                              0.611                     0.0000002                    88                  (24)
NOG                                                                 Noggin.                                                       0.421                     0.0000311                    93                  (22)
CD34                                               Cluster of differentiation 34                                    −0.0093                   0.931                            88                  (23)
CDCP1                                     CUB domain-containing protein 1.                                 0.119                     0.268                            88                  (25)
THY1                                Thymocyte differentiation antigen 1, or CD90.                       0.143                     0.206                            80                  (26)
ALDH1A1                        Aldehyde dehydrogenase 1 family member A1.                      0.0788                   0.483                            81                  (21)
ALDH1A3                        Aldehyde dehydrogenase 1 family member A3.                    −0.0177                   0.888                            65                  (21)
ALDH1B1                        Aldehyde dehydrogenase 1 family member B1.                    −0.0871                   0.416                            89                  (27)
LMNA/C                                                       Lamin A/C.                                                    0.0884                   0.396                            94                  (28)
LMNB1                                                          Lamin B1.                                                   −0.19                       0.067                            94                  (28)
NRP1                                                            Neuropilin 1                                                   0.197                     0.066                            88                  (29)
NRP2                                                           Neuropilin 2.                                                −0.0796                   0.46                              88                  (30)
PMSA2                     Proteasome (prosome, macropain) subunit, alpha type, 2               0.0772                   0.466                            91                  (31)
FLT1                                              Fms-related tyrosine kinase 1                                     0.0247                   0.818                            89                  (32)
KDR                                               Kinase insert domain receptor                                     0.0173                   0.872                            89                  (33)
FLT4                                              Fms-related tyrosine kinase 4                                     0.033                     0.753                            93                  (34)
SNAI1                                     Snail family transcriptional repressor 1                             0.0996                   0.381                            79                  (35)
SNAI2                                     Snail family transcriptional repressor 2                             0.0352                   0.74                              91                  (35)
TWIST1                                Twist family bHLH transcription factor 1.                         −0.0641                   0.548                            90                  (36)
SELL                                                              Selectin L                                                     0.0105                   0.927                            78                  (37)
SELE                                                              Selectin E                                                   −0.158                     0.165                            79                  (37)
SELP                                                              Selectin P.                                                   −0.0961                   0.396                            80                  (37)
NOTCH2                                                  Notch receptor 2                                             −0.0981                   0.354                            91                  (38)
NOTCH1                                                  Notch receptor 1                                                0.044                     0.675                            93                  (38)
PECAM1                           Platelet endothelial cell adhesion molecule 1.                        0.0484                   0.651                            89                  (39)
STAT5                             Signal transducer and activator of transcription 5                   −0.0296                   0.782                            90                  (40)
CD133                                            Cluster of differentiation 133                                     0.149                     0.172                            86                  (23)
factor in 85-90% of cancers types, with alternative pathways
accounting for the remainder (43). However, recent evidence
has suggested that in addition to telomere lengthening, TERT
may have a role in endothelial–mesenchymal transformation,
as well as in the induction of stemness (44, 45). 
Classically, it was believed that tumours consisted of
uniformly neoplastic cells capable of proliferating
independently, and giving rise to new clonal lineages which
may contribute to the emergence of therapeutic resistance or
to relapse of the disease after the end of adjuvant therapy.
This has been referred to as the clonal evolution model, and
was initially elucidated in 1976 by Nowell (46). The high
degree of allelic heterogeneity seen in cancerous cells within
solid tumours and in situ lesions is believed to be due to
clonal neoplastic expansion, as would be predicted by the
clonal evolutionary model (47, 48).
However, over the past three decades, evidence has been
cited in favour of a tumour progression model which posits
a hierarchy among the clonal lineages, privileging a small
sub-population of pluripotential cells with known stem cell
markers. This has been labelled as the cancer stem-cell
(CSC) hypothesis. This was initially described by Bonnet
and Dick in 1997 in the context of acute myelogenous
leukaemia (49). In 2003, Al Hajj et al. showed that all cells
within a solid breast tumour were not capable of generating
a tumour when injected into nonobese diabetic/severe
combined immunodeficiency (NOD/SCID) mice, and
identified cells with a CD44+/CD24− phenotype to be
capable of pluripotential differentiation (50). Subsequently,
CSCs were identified in melanoma (51), and neoplasias of
the brain (52), lung (53), prostate (54) and colon (55). Other
markers, most significantly acetaldehyde dehydrogenase 1
(ALDH1), have also been identified (56).
Whilst both of these hypotheses have broad similarities, they
have very varied and mutually exclusive clinical implications,
particularly with regards to treatment of relapsing disease and
therapeutic resistance. Most current treatment modalities target
proliferating cells indiscriminatingly. Such an approach would
be expected to select clonal lineages more likely to be resistant
to treatment, and potentially result in relapse in the disease
after adjuvant treatment (57). However, if a progenitor
population of pluripotential cells is positively identified, it
would provide a discrete therapeutic target whose obliteration
could potentially reverse the pathology (58).
However, issues have arisen with regards to the purported
role of CSCs. There has been a failure in consistent
replication of findings. There have been queries whether
immunodeficient mice provide a suitable microenvironment
to replicate in vivo conditions of human cancer (57).
Furthermore, the use of proteolytic enzymes in the
processing of tumours before sorting by flow cytometry has
been cited as a destructive process which may affect the
quality and reliability of the samples studied (57, 59). 
Being that as it may, the mRNA expression levels of stem
cell markers, such as CD44 and ALDH1, have been found to
be predictive of poor prognosis in breast carcinoma,
suggesting that so-called ‘stem-ness’ is likely to have a role
in solid tumours (56, 60).
More recently, it has been suggested that a viable model
of tumour progression would be midway between clonal
evolution and stem cell-based clonal hierarchy, likely with
certain clonal lineages acquiring stem cell-like qualities
under certain conditions (15).
By examining the association between known stem cell
markers and TERT, we hope to link two highly influential
concepts regarding our understanding of oncogenesis. By
stratifying the multitude of stem cell markers by their
correlation with TERT, an oncogenic molecule for which the
evidence base has attained a degree of maturity, we hope to
have provided an addition avenue of enquiry for research in
breast tumour heterogeneity and clonal dynamics. This
knowledge would hopefully enable more tailored treatments
for recurrent and relapsing disease.
Several of the molecules identified in our study have been
shown to have roles in oncogenesis. Prominent among these is
POU5F1 (better known as OCT4), which has been identified as
an essential transcription factor mediating stem-ness. Shen and
colleagues studied the effects of overexpression of POU5F1 in
MDA-MB-231 and 4T1 breast cancer cell lines, and found that
the overexpression of POU5F1 suppressed migration and
invasion in these usually aggressive cell types (20).
NES has been identified as a marker of poor prognosis in
ovarian (61), breast (62) and pancreatic (63) neoplasia.
CD24, CD29 and CD44 have been studied as markers for
colonic CSCs (64). BMI1 has been shown to have a role in
mediating bone metastasis in breast cancer (18, 65).
Similarly, evidence of a role in cancer has been suggested in
the literature for the molecules identified as interacting with
TERT in this study (8, 9).
However, certain limitations have to be acknowledged in
our study. We were limited to mRNA expression data for a
cohort for which we do not have information regarding protein
expression. Furthermore, in vitro studies in transfected cell
lines would be required to better characterise the effects of
knocked-down and ectopic expression of these molecules, as
well as to be able to delineate the interactions which may
mediate their effects. By highlighting this subset of stem cell
markers and their relation with TERT, we believe we have
identified a potentially important direction of enquiry in
understanding the role of stem-ness in breast cancer.
Conclusion
CSCs continue to be an important if challenging research
question. An understanding of their role in tumour progression
would go a long way in enabling more tailored treatments of
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human breast cancer. We believe that the evidence we
presented in this article of possible interactions between TERT
and a discrete subset of known stem cell markers would
significantly contribute to further enquiries regarding clonal
dynamics in the context of human breast cancer.
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